An interdisciplinary research team from Leipzig University and the Saxon AI center ScaDS.AI has developed a novel approach ...
Wide areas of the pharmaceutical industry are ripe for enhancement, as examples from the industry’s top innovators reflect.
Former DeepMind employees raise $40 million to launch London-based startup 'laser-focused' on AI protein design.
Variational AI, the company behind Enki™, an advanced foundation model for small molecule drug discovery, today announced the completion of its oversubscribed $US5.5 million Seed extension round.
Isomorphic Labs, a spin-off from DeepMind, is applying AI-first principles to drug discovery rather than just protein ...
AI creates anti-cancer molecules for proteins that previously could not be targeted pharmacologically by leveraging quantum ...
A federal judge will soon decide whether to dismiss a lawsuit against UnitedHealth Group alleging that the company and its ...
AI helps scientists decode a cone snail toxin’s targets, paving the way for safer drug development and ecological research.
Latent Labs has raised $50 million of new funding as it commercialises its GenAI technology for designing new proteins for ...
Former DeepMind scientist Simon Kohl has raised $50 million for Latent Labs, a London-based AI startup aiming to transform ...
Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...
Backed by influencial names in the life sciences industry, Latent Labs offers an AI platform to accelerate and improve drug ...